[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs]

Ned Tijdschr Geneeskd. 1999 Aug 7;143(32):1649-52.
[Article in Dutch]

Abstract

NSAID gastropathy, because of its severity and prevalence, is the most important side effect of nonsteroidal anti-inflammatory drugs. Protective strategies are advocated in patients with high risk for NSAID gastropathy (age over 60 years and/or previous ulcer). Different strategies for the prevention of NSAID gastropathy are: using a cyclo-oxygenase (COX)-2 inhibitor, adding a prostaglandin analogue, an H2-receptor antagonist or a proton pump inhibitor or eradicating Helicobacter pylori. On the basis of efficacy, safety and costs prescription of a proton pump inhibitor as a prophylactic agent appears to be the best option; prescription of a prostaglandin analogue is a good alternative. The preliminary data on the COX-2 inhibitors are promising. The role of H. pylori in NSAID gastropathy is not yet elucidated.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Ulcer Agents / therapeutic use
  • Cyclooxygenase Inhibitors / therapeutic use
  • Drug Therapy, Combination
  • Helicobacter Infections / prevention & control
  • Helicobacter pylori
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Prostaglandin Antagonists / therapeutic use
  • Stomach Diseases / chemically induced*
  • Stomach Diseases / microbiology
  • Stomach Diseases / prevention & control*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anti-Ulcer Agents
  • Cyclooxygenase Inhibitors
  • Histamine H2 Antagonists
  • Prostaglandin Antagonists